Between 2020 and 2024, the number of unique sites in the United States where phase I clinical trials for non-small cell lung cancer (NSCLC) were conducted decreased by 44% and became increasingly ...
The past decade has seen many innovations in clinical trials, including new trial formats 1, novel endpoints 2, new biomarkers and ways of stratifying patients 3, a broader set of data sources such as ...
Between 2020 and 2024, the number of unique sites in the United States where phase I clinical trials for non-small cell lung cancer (NSCLC) were conducted decreased by 44% and became increasingly ...
For more than a decade now, the global landscape of immuno-oncology (IO) clinical trials has been dominated by studies testing PD1 and PDL1 inhibitors, whether as monotherapy or in combinations.
The mismatch between the study populations participating in oncology clinical trials and the composition of the targeted cancer population requires urgent amelioration. Regulatory requirements can ...
SAN DIEGO – Between 2020 and 2024, the number of unique sites in the United States where phase I clinical trials for non-small cell lung cancer (NSCLC) were conducted decreased by 44% and became ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results